Reassessing the Current UICC/AJCC TNM Staging for Renal Cell Carcinoma

European Urology

Volumn 56, Issue 4, 2009, Pages 636-643

  Moch, Holger ^a   Artibani, Walter ^b   Delahunt, Brett ^c   Ficarra, Vincenzo ^b   Knuechel, Ruth ^d   Montorsi, Francesco ^e   Patard, Jean Jacques ^f   Stief, Christian G ^g   Sulser, Tullio ^a   Wild, Peter J ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f UNIVERSITÉ DE RENNES 1   (France)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Biological tumour markers; Renal cell carcinoma; Review; Staging neoplasm

Indexed keywords

ADRENAL METASTASIS; CANCER INFILTRATION; CANCER INVASION; CANCER STAGING; CAVA VEIN; HUMAN; HUMAN TISSUE; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY VEIN THROMBOSIS; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR VOLUME;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM STAGING;

EID: 69249209707     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.06.036     Document Type: Review

References (62)

1. In: Greene F.L., Page D.L., Fleming I.D., et al. (Eds). AJCC cancer staging manual. 6th ed. (2002), Springer, New York, NY
2. Goel M.C., Mohammadi Y., Sethi A.S., Brown J.A., and Sundaram C.P. Pathologic upstaging after laparoscopic radical nephrectomy. J Endourol 22 (2008) 2257-2261
3. Srigley J.R., Hutter R.V., Gelb A.B., et al. Current prognostic factors-renal cell carcinoma: Workgroup No. 4. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80 (1997) 994-996
4. Ficarra V., Galfano A., Mancini M., Martignoni G., and Artibani W. TNM staging system for renal-cell carcinoma: current status and future perspectives. Lancet Oncol 8 (2007) 554-558
5. Griffiths I.H., and Thackray A.C. Parenchymal carcinoma of the kidney. Br J Urol 21 (1949) 128-151
6. Flocks R.H., and Kadesky M.C. Malignant neoplasms of the kidney; an analysis of 353 patients followed five years or more. J Urol 79 (1958) 196-201
7. Petkovic S.D. An anatomical classification of renal tumors in the adult as a basis for prognosis. J Urol 81 (1959) 618-623
8. Robson C.J. Radical nephrectomy for renal cell carcinoma. J Urol 89 (1963) 37-42
9. Robson C.J., Churchill B.M., and Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 101 (1969) 297-301
10. Delahunt B. Histopathologic prognostic indicators for renal cell carcinoma. Semin Diagn Pathol 15 (1998) 68-76
11. In: Harmen M.H. (Ed). TNM classification of malignant tumours (1978), Union Internationale Contre le Cancer, Geneva, Switzerland
12. In: Hermanek P., and Sobin L.H. (Eds). TNM classification of malignant tumours. 4th ed. (1987), Springer, Berlin, Germany
13. In: Hermanek P., Henson D.E., Hutter R.V., and Sobin L.H. (Eds). TNM supplement. A commentary on uniform use (1993), Springer, Berlin, Germany
14. In: Sobin L.H., and Wittekind C.L. (Eds). TNM classification of malignant tumours. 5th ed. (1997), Wiley-Liss, New York, NY
15. Hafez K.S., Fergany A.F., and Novick A.C. Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol 162 (1999) 1930-1933
16. Kinouchi T., Saiki S., Meguro N., et al. Impact of tumor size on the clinical outcomes of patients with Robson State I renal cell carcinoma. Cancer 85 (1999) 689-695
17. Gettman M.T., Blute M.L., Spotts B., Bryant S.C., and Zincke H. Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer 91 (2001) 354-361
18. Zisman A., Pantuck A.J., Chao D., et al. Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome. J Urol 166 (2001) 54-58
19. Delahunt B., Kittelson J.M., McCredie M.R., Reeve A.E., Stewart J.H., and Bilous A.M. Prognostic importance of tumor size for localized conventional (clear cell) renal cell carcinoma: assessment of TNM T1 and T2 tumor categories and comparison with other prognostic parameters. Cancer 94 (2002) 658-664
20. Moch H., Gasser T., Amin M.B., Torhorst J., Sauter G., and Mihatsch M.J. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 89 (2000) 604-614
21. Bedke J., Pritsch M., Buse S., et al. Prognostic stratification of localized renal cell carcinoma by tumor size. J Urol 180 (2008) 62-67
22. Uzzo R.G., and Novick A.C. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol 166 (2001) 6-18
23. Ficarra V., Schips L., Guille F., et al. Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer 104 (2005) 968-974
24. Antonelli A., Cozzoli A., Nicolai M., et al. Nephron-sparing surgery versus radical nephrectomy in the treatment of intracapsular renal cell carcinoma up to 7 cm. Eur Urol 53 (2008) 803-809
25. Patard J.J., Shvarts O., Lam J.S., et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 171 (2004) 2181-2185
26. Leibovich B.C., Blute M.L., Cheville J.C., Lohse C.M., Weaver A.L., and Zincke H. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 171 (2004) 1066-1070
27. Elmore J.M., Kadesky K.T., Koeneman K.S., and Sagalowsky A.I. Reassessment of the 1997 TNM classification system for renal cell carcinoma. Cancer 98 (2003) 2329-2334
28. Ficarra V., Guille F., Schips L., et al. Proposal for revision of the TNM classification system for renal cell carcinoma. Cancer 104 (2005) 2116-2123
29. Ficarra V., Novara G., Galfano A., and Artibani W. Neoplasm staging and organ-confined renal cell carcinoma: a systematic review. Eur Urol 46 (2004) 559-564
30. Ficarra V., Prayer-Galetti T., Novella G., et al. Incidental detection beyond pathological factors as prognostic predictor of renal cell carcinoma. Eur Urol 43 (2003) 663-669
31. Patard J.-J., Tazi H., Bensalah K., et al. The changing evolution of renal tumours: a single center experience over a two-decade period. Eur Urol 45 (2004) 490-494
32. Roberts W.W., Bhayani S.B., Allaf M.E., Chan T.Y., Kavoussi L.R., and Jarrett T.W. Pathological stage does not alter the prognosis for renal lesions determined to be stage T1 by computerized tomography. J Urol 173 (2005) 713-715
33. Jung S.J., Ro J.Y., Truong L.D., Ayala A.G., and Shen S.S. Reappraisal of T3N0/NxM0 renal cell carcinoma: significance of extent of fat invasion, renal vein invasion, and adrenal invasion. Hum Pathol 39 (2008) 1689-1694
34. Yoo C., Song C., Hong J.H., Kim C.S., and Ahn H. Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma. J Urol 180 (2008) 486-491 discussion 491
35. Lam J.S., Klatte T., Patard J.-J., et al. Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur Urol 52 (2007) 155-162
36. Siemer S., Lehmann J., Loch A., et al. Current TNM classification of renal cell carcinoma evaluated: revising stage T3a. J Urol 173 (2005) 33-37
37. Siddiqui S.A., Frank I., Leibovich B.C., et al. Impact of tumor size on the predictive ability of the pT3a primary tumor classification for renal cell carcinoma. J Urol 177 (2007) 59-62
38. Han K.R., Bui M.H., Pantuck A.J., et al. TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. J Urol 169 (2003) 899-903
39. Thompson R.H., Leibovich B.C., Cheville J.C., et al. Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a?. J Urol 173 (2005) 918-921
40. Thompson R.H., Cheville J.C., Lohse C.M., et al. Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer 104 (2005) 53-60
41. Ficarra V., Novara G., Iafrate M., et al. Proposal for reclassification of the TNM staging system in patients with locally advanced (pT3-4) renal cell carcinoma according to the cancer-related outcome. Eur Urol 51 (2007) 722-731
42. Bonsib S.M., Gibson D., Mhoon M., and Greene G.F. Renal sinus involvement in renal cell carcinomas. Am J Surg Pathol 24 (2000) 451-458
43. Thompson R.H., Leibovich B.C., Cheville J.C., et al. Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma?. J Urol 174 (2005) 1218-1221
44. Margulis V., Tamboli P., Matin S.F., Meisner M., Swanson D.A., and Wood C.G. Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma. J Urol 178 (2007) 1878-1882
45. Bonsib S.M. Renal lymphatics, and lymphatic involvement in sinus vein invasive (pT3b) clear cell renal cell carcinoma: a study of 40 cases. Mod Pathol 19 (2006) 746-753
46. Bonsib S.M. Renal veins and venous extension in clear cell renal cell carcinoma. Mod Pathol 20 (2007) 44-53
47. Kim H.L., Zisman A., Han K.R., Figlin R.A., and Belldegrun A.S. Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different?. J Urol 171 (2004) 588-591
48. Moinzadeh A., and Libertino J.A. Prognostic significance of tumor thrombus level in patients with renal cell carcinoma and venous tumor thrombus extension. Is all T3b the same?. J Urol 171 (2004) 598-601
49. Leibovich B.C., Cheville J.C., Lohse C.M., et al. Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved?. J Urol 173 (2005) 716-719
50. Ficarra V., Galfano A., Guille F., et al. A new staging system for locally advanced (pT3-4) renal cell carcinoma: a multicenter European study including 2,000 patients. J Urol 178 (2007) 418-424
51. Terrone C., Gontero P., Volpe A., et al. Proposal of an improved prognostic classification for pT3 renal cell carcinoma. J Urol 180 (2008) 72-78
52. Terrone C., Cracco C., Guercio S., et al. Prognostic value of the involvement of the urinary collecting system in renal cell carcinoma. Eur Urol 46 (2004) 472-476
53. Klatte T., Chung J., Leppert J.T., et al. Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma. BJU Int 99 (2007) 821-824
54. Karakiewicz P.I., Trinh Q.-D., Bhojani N., et al. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol 51 (2007) 1616-1624
55. Lohse C.M., and Cheville J.C. A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma. Clin Lab Med 25 (2005) 433-464
56. Terrone C., Cracco C., Porpiglia F., et al. Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol 49 (2006) 324-331
57. Blom J.H.M., van Poppel H., Maréchal J.M., et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol 55 (2009) 28-34
58. Motzer R.J., Bacik J., Murphy B.A., Russo P., and Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20 (2002) 289-296
59. Leibovich B.C., Cheville J.C., Lohse C.M., et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol 174 (2005) 1759-1763
60. Reeves D.J., and Liu C.Y. Treatment of metastatic renal cell carcinoma. Cancer Chemother Pharmacol 64 (2009) 11-25
61. Maluf F.C., Fernandes Gdos S., Kann A.G., Aguilar-Ponce J.L., de la Garza J., and Buzaid A.C. Exploring the role of novel agents in the treatment of renal cell carcinoma. Cancer Treat Rev 34 (2008) 750-760
62. Gospodarowicz M.K., Miller D., Groome P.A., Greene F.L., Logan P.A., and Sobin L.H. The process for continuous improvement of the TNM classification. Cancer 100 (2004) 1-5